Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Systems and methods for HDMI signal communication over an optical communication link are described. One aspect includes receiving an HDMI control signal from an HDMI master device, and another HDMI control signal from an HDMI sink terminal via a communication resources. The method identifies half-duplex communication resource contention between the HDMI control signal and the other HDMI control signal, and transitions a communication direction of the half-duplex communication resources to give the HDMI control signal precedence over the other HDMI control signal. Subsequent to transitioning the communication direction, the method transfers the HDMI control signal to the HDMI sink terminal via the communication resources. Subsequent to transferring the HDMI control signal, the method again transitions the direction of the half-duplex communication resources, and transfers the other HDMI control signal to the HDMI master device.

Abstract: Systems and methods for HDMI signal communication over an optical communication link are described. One aspect includes receiving an HDMI control signal from an HDMI master device, and another HDMI control signal from an HDMI sink terminal via a communication resources. The method identifies half-duplex communication resource contention between the HDMI control signal and the other HDMI control signal, and transitions a communication direction of the half-duplex communication resources to give the HDMI control signal precedence over the other HDMI control signal. Subsequent to transitioning the communication direction, the method transfers the HDMI control signal to the HDMI sink terminal via the communication resources. Subsequent to transferring the HDMI control signal, the method again transitions the direction of the half-duplex communication resources, and transfers the other HMDI control signal to the HDMI master device.

Abstract: Systems and methods for signal communication over an optical link are described. One aspect includes receiving a source CONFIG1 signal from a DP master device and a sink CONFIG1 signal from a sink terminal. The source and sink CONFIG1 signals are analyzed. It is determined whether a signal transmission mode is a DP protocol. For a DP protocol, a pair of source AUX signals is received from the DP master device. A pair of sink AUX signals is received from the sink terminal. Communication resource contention between the source and sink AUX signals is identified. A communication direction of the communication resources is transitioned to give the source AUX signals precedence over the sink AUX signals. The source AUX signals are transferred to the sink terminal via the communication resources. The direction of the communication resources is again transitioned. The sink AUX signals are transferred to the DP master device.

Abstract: Systems and methods related to battery triggering for activation of an optical data interconnect system are described. One aspect includes signal conversion electronics configured to convert received optical signals to an electrical signal. An amplifier may convert the electrical signal to differential electrical signals and transmit the differential electrical signals to a sink. A first conductor and a second conductor may interface the amplifier with a sink side resistor network. The first conductor and the second conductor may conduct a composite signal including the differential electrical signals and a first power signal from the sink side resistor network. A filter connected to the first conductor and the second conductor may be configured to receive the composite signal, filter a second power signal from the composite signal that is at least a portion of the first power signal, and connect the second power signal to the amplifier via power distribution circuitry.

Abstract: Systems and methods related to battery triggering for activation of an optical data interconnect system are described. One aspect includes signal conversion electronics configured to convert received optical signals to an electrical signal. A battery triggering circuit may trigger a sink responsive to detecting connection of the electronics to the sink. An amplifier may convert the electrical signal to differential electrical signals and transmit the signals to the sink. A first and a second conductor may interface the amplifier with a sink side resistor network powered responsive to the triggering the sink, and conduct a composite signal including the differential electrical signals and a power signal from the sink side resistor network. A filter connected to the conductors may receive the composite signal, filter a second power signal from the composite signal, and connect the second power signal to the amplifier and the battery triggering circuit via power distribution circuitry.

Abstract: Systems and methods related to battery triggering for activation of an optical data interconnect system are described. One aspect includes signal conversion electronics configured to convert received optical signals to an electrical signal. An amplifier may convert the electrical signal to differential electrical signals and transmit the differential electrical signals to a sink. A first conductor and a second conductor may interface the amplifier with a sink side resistor network. The first conductor and the second conductor may conduct a composite signal including the differential electrical signals and a first power signal from the sink side resistor network. A filter connected to the first conductor and the second conductor may be configured to receive the composite signal, and filter a second power signal from the composite signal that is at least a portion of the first power signal. A voltage regulator may connect the second power signal to the amplifier.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A winding device for a non-stay-cord venetian blind is disclosed, which comprises a fixing seat, a fixer, winding drums with one-way dampers, a rear cover and iron cores. A non-stay-cord venetian blind adopting the winding device is also disclosed, which comprises a top beam, a bottom beam, slats, cords, a winding device, a motor and a shaft. The winding device adopts a unique separate settlement for the motor, which is convenient for mounting and displacement and easy to roll up and down. During the operation, the non-stay-cord venetian blind keeps horizontal and the bottom beam does not slide down or bounce back in any positions. The winding device is able to be applied on blinds adopt strip or string shaped ladder tape or blinds with center holes, side holes or side slots on the slats. Multiple cords are able to be winded the same winding drum.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors.

Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.